Strategies for the use of immune checkpoint inhibitors.
作者信息
Matsumura Noriomi
机构信息
Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
出版信息
Int Cancer Conf J. 2021 Sep 3;10(4):265. doi: 10.1007/s13691-021-00508-9. eCollection 2021 Oct.
Abstract
摘要
相似文献
1
Strategies for the use of immune checkpoint inhibitors.免疫检查点抑制剂的使用策略。
Int Cancer Conf J. 2021 Sep 3;10(4):265. doi: 10.1007/s13691-021-00508-9. eCollection 2021 Oct.
2
Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.晚期尿路上皮癌中免疫检查点抑制剂的未来策略。
Curr Treat Options Oncol. 2020 Dec 2;22(1):7. doi: 10.1007/s11864-020-00799-9.
3
Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review.除远隔效应外，提高癌症免疫检查点抑制剂疗效的策略：一项系统综述
Cancers (Basel). 2019 Apr 15;11(4):539. doi: 10.3390/cancers11040539.
4
Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab.免疫检查点抑制剂的替代剂量策略以提高成本效益：特别关注纳武利尤单抗和帕博利珠单抗。
Lancet Oncol. 2022 Dec;23(12):e552-e561. doi: 10.1016/S1470-2045(22)00554-X.
5
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.免疫检查点抑制剂与癌症治疗中抗生素相互作用的分析。
Front Med. 2022 Jun;16(3):307-321. doi: 10.1007/s11684-022-0927-0. Epub 2022 Jun 1.
6
CTLA-4 and its inhibitors in esophageal cancer: efficacy of therapy and potential mechanisms of adverse events.CTLA-4及其抑制剂在食管癌中的应用：治疗效果及不良事件的潜在机制
Am J Cancer Res. 2023 Jul 15;13(7):3140-3156. eCollection 2023.
7
Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy.免疫检查点抑制剂在乙型肝炎病毒所致肝细胞癌治疗中的应用
Vaccines (Basel). 2023 Mar 8;11(3):614. doi: 10.3390/vaccines11030614.
8
Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities.克服肝细胞癌对免疫检查点抑制剂的耐药性：挑战与机遇
Front Oncol. 2022 Sep 2;12:958720. doi: 10.3389/fonc.2022.958720. eCollection 2022.
9
The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.免疫检查点抑制剂在结直肠癌治疗中的出现。
Curr Drug Targets. 2021;22(9):1021-1033. doi: 10.2174/1389450122666210204204415.
10
Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall.免疫检查点抑制剂与动脉粥样硬化性心血管疾病风险之间的关联：墙上的又一块砖。
Int J Mol Sci. 2024 Feb 21;25(5):2502. doi: 10.3390/ijms25052502.
本文引用的文献
1
Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy.纳武单抗联合伊匹木单抗治疗伴肉瘤样成分的复发性转移性肾细胞癌的病理完全缓解
Int Cancer Conf J. 2021 Jul 16;10(4):285-289. doi: 10.1007/s13691-021-00501-2. eCollection 2021 Oct.
2
Conversion surgery of Stage IV gastric cancer with peritoneal dissemination after nivolumab.纳武单抗治疗后伴有腹膜播散的IV期胃癌的转化手术
Int Cancer Conf J. 2021 Jul 22;10(4):280-284. doi: 10.1007/s13691-021-00503-0. eCollection 2021 Oct.
3
Hepatectomy and immune checkpoint inhibitor treatment for liver metastasis originating from non-cutaneous melanoma: a report of three cases.肝切除术联合免疫检查点抑制剂治疗非皮肤黑色素瘤肝转移：三例报告
Int Cancer Conf J. 2021 Jun 15;10(4):274-279. doi: 10.1007/s13691-021-00495-x. eCollection 2021 Oct.
4
Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art.新辅助免疫检查点抑制剂在癌症中的应用：当前的最新进展。
Crit Rev Oncol Hematol. 2021 Jan;157:103172. doi: 10.1016/j.critrevonc.2020.103172. Epub 2020 Nov 12.
Zotero 插件